IDEAYA Shares Surge After Positive Phase 2/3 Results in Hard-to-Treat Eye Cancer
New drug combo shows strong results in rare eye cancer, slowing disease and shrinking tumors; approval filing planned for 2026.
/ 4 items
#IDYA↓
IDEAYA Gets FDA Green Light for Groundbreaking Cancer Treatment
IDEAYA Biosciences receives FDA clearance for IDE034, a first-in-class dual-target cancer therapy aimed at lung, colorectal, and head and neck tumors.
Ideaya Biosciences Stock Jumps on Promising Eye Cancer Treatment Results
Ideaya Biosciences shares rise after reporting breakthrough survival data for rare eye cancer treatment combining darovasertib with Pfizer's Xalkori in clinical trial.
IDEAYA's IDE849 Shows Strong Promise for Lung Cancer Patients
IDE849, a new DLL3-targeting drug for SCLC, shows strong efficacy with high response rates (up to 77.1%) and activity in brain metastases. It has a manageable safety profile, offering new hope for patients.